(Reuters) – Advisers to the U.S. health regulator on Thursday voted in favor of recommending a full approval for Pfizer’s COVID-19 pill Paxlovid in adults at high risk of progression to severe disease.
The Food and Drug Administration’s panel of external advisers voted 16-to-1 in favor of the drug’s benefits outweighing its risk for some adults with mild-to-moderate COVID-19.
(Reporting by Leroy Leo and Khushi Mandowara in Bengaluru; Editing by Maju Samuel)
